SGD Pharma announces the appointment of Fabio Invernizzi, General Manager West Business Unit

Paris La Défense, FRANCE: SGD Pharma, global primary glass packaging leader, has announced the appointment of Fabio Invernizzi as its new General Manager of its West BU. The BU West includes SGD Pharma’s commercial activities for MEA, North and South America and our manufacturing footprint in Europe. Fabio joins the Group Executive Committee bringing over 15 years of experience in Commercial, Marketing and Business Development at a senior level for the life science industry. He joins SGD Pharma following his last position as Vice-President and EMEA BU Head of Capsules and Health Ingredients at Lonza. Prior to that role, Fabio led the Global Commercial & Business Development activities for the Capsules & Heath Ingredients Division at Lonza. 

Commenting on his appointment, Fabio said: “In starting this next chapter, I am excited to join the experienced SGD Pharma team working alongside CEO Olivier Rousseau and the Executive Committee. I am eager to continue writing the success story of SGD Pharma with my team and colleagues - I believe we can bring the company to the next level of leadership in Europe in the Primary Pharmaceutical Packaging market. Together with the strong team in place, I also look forward to continuing to grow in the Americas.”

Fabio picks up the baton of West BU General Manager from Laurent Zuber, who will retire in January 2024 after a long lasting and successful career at Saint-Gobain and SGD Pharma. SGD Pharma would like to thank Laurent Zuber who led the commercial activities of the group and the General Management of the West BU with passion and dedication. The company also shares its deep gratitude to Laurent for building the customer relationships it has today and for expanding its product portfolio in molded and tubular. 

For more information about SGD Pharma please visit: https://www.sgd-pharma.com. 

 

Marketing & Communication SGD Pharma  

Jean-Pascal Marquié – jean-pascal.marquie@sgdgroup.com    

17.01.2024, SGD Pharma

News material on the Site is copyright and belongs to the Company or to its third party news provider, and all rights are reserved. Any User who accesses such material may do so only for its own personal use, and the use of such material is at the sole risk of the User. Redistribution or other commercial exploitation of such news material is expressly prohibited. Where such news material is provided by a third party, each User agrees to observe and be bound by the specific terms of use applying to such news material. We do not represent or endorse the accuracy or reliability of any of the info contained in any news or external websites referred to in the news.

Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.